These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38379744)

  • 21. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Respiratory syncytial virus detection in cells and clinical samples by using three new monoclonal antibodies.
    Gómez RS; Mora JE; Cortés CM; Riedel CA; Ferrés M; Bueno SM; Kalergis AM
    J Med Virol; 2014 Jul; 86(7):1256-66. PubMed ID: 24150877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis.
    Jacque E; Chottin C; Laubreton D; Nogre M; Ferret C; de Marcos S; Baptista L; Drajac C; Mondon P; De Romeuf C; Rameix-Welti MA; Eléouët JF; Chtourou S; Riffault S; Perret G; Descamps D
    Front Immunol; 2021; 12():683902. PubMed ID: 34163482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies.
    Gimenez HB; Chisholm S; Dornan J; Cash P
    Clin Diagn Lab Immunol; 1996 May; 3(3):280-6. PubMed ID: 8705669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Respiratory syncytial virus disease morbidity in Australian infants aged 0 to 6 months: a systematic review with narrative synthesis.
    Self A; Van Buskirk J; Clark J; Cochrane JE; Knibbs L; Cass-Verco J; Gupta L
    BMC Public Health; 2023 Dec; 23(1):2560. PubMed ID: 38129854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.
    Caidi H; Harcourt JL; Tripp RA; Anderson LJ; Haynes LM
    PLoS One; 2012; 7(12):e51485. PubMed ID: 23300550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
    Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Atwell JE; Lutz CS; Sparrow EG; Feikin DR
    Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity.
    Rzymski P; Gwenzi W
    J Med Virol; 2024 Feb; 96(2):e29453. PubMed ID: 38305000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.
    Giersing BK; Karron RA; Vekemans J; Kaslow DC; Moorthy VS
    Vaccine; 2019 Nov; 37(50):7355-7362. PubMed ID: 28302410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
    Ren S; Chen Q; Zhang Y; Yi L; Qian C; Lu Y; Shen J; Liu X; Jiang M; Wang B; Song J; Shao X; Zhang T; Tian J; Zhao G
    Vaccine; 2024 Jan; 42(2):352-361. PubMed ID: 38057209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
    DeVincenzo JP; Aitken J; Harrison L
    J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood.
    Scotta MC; Stein RT
    J Pediatr (Rio J); 2023; 99 Suppl 1(Suppl 1):S4-S11. PubMed ID: 36402228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development and properties of neutralizing monoclonal antibodies for fusion protein of respiratory syncytial virus.].
    Kushch AA; Klimova RR; Fedorova NE; Masalova OV; Niconova AA; Lesnova EI; Momotyuk ED; Demidova NA; Samartseva TG; Zverev VV
    Vopr Virusol; 2019; 64(2):90-96. PubMed ID: 31412175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.